Condition: Fuchs Endothelial Corneal Dystrophy · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.
This description comes directly from the study's public registry record.
Gilles THURET, MD PhD · (0)4 77 12 77 96 · gilles.thuret@univ-st-etienne.fr
Clara Pfenninger, PhD · (0)4 77 12 02 87 · clara.pfenninger@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| CHU de Saint-Etienne | Saint-Etienne, France, France | Recruiting |
| Hopital de Mercy | Metz, Metz, France | Not Yet Recruiting |
| Cochin Hospital | Paris, Paris, France | Not Yet Recruiting |
| Hôpital Fondation Rothschild | Paris, Paris, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Rouen | Rouen, Rouen, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07539012